The History of Early Breast Cancer Treatment

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

(2022) Rosie Bradley et al.   LANCET ONCOLOGY

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

(2021) Erica L Mayer et al.   LANCET ONCOLOGY

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

(2021) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

(2021) Andrew N.J. Tutt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

(2020) Junjie Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

(2020) Stephen R. D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

(2020) Philip M Poortmans et al.   LANCET ONCOLOGY

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

(2019) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

(2019) Kenji Tamura et al.   LANCET ONCOLOGY

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

(2019) Seock-Ah Im et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study

(2019) Johan Staaf et al.   NATURE MEDICINE

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

(2019) Olivia Pagani et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

(2018) Noah Kornblum et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients

(2017) Mirelle Lagendijk et al.   INTERNATIONAL JOURNAL OF CANCER

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis

(2017) Armando E. Giuliano et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

(2017) Charlotte E Coles et al.   LANCET

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

(2017) Norikazu Masuda et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer

(2016) Lise Bech Jellesmark Thorsen et al.   JOURNAL OF CLINICAL ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial

(2015) Lorenzo Livi et al.   EUROPEAN JOURNAL OF CANCER

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer

(2015) Philip M. Poortmans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

(2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group)   LANCET

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

A Systematic Review of Complications of Implant-based Breast Reconstruction with Prereconstruction and Postreconstruction Radiotherapy

(2013) Adeyiza O. Momoh et al.   ANNALS OF SURGICAL ONCOLOGY

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

(2013) Judith Hurley et al.   BREAST CANCER RESEARCH AND TREATMENT

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer

(2013) Judy C. Boughey   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial

(2013) Umberto Veronesi et al.   LANCET ONCOLOGY

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

(2013) Thorsten Kuehn et al.   LANCET ONCOLOGY

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Association Between Treatment With Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival Among Older Women With Invasive Breast Cancer

(2012) Grace L. Smith et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial

(2012) Saskia Litière et al.   LANCET ONCOLOGY

Finding CDK: Linking yeast with humans

(2012) Paul Nurse   NATURE CELL BIOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer

(2006) V Craig Jordan   BRITISH JOURNAL OF PHARMACOLOGY